title: [Malignancies of the skin and immunomodulatory antirheumatic therapy].
abstract: For the clinical practice there is uncertainty as to what degree the therapeutic immunomodulation of rheumatoid arthritis (RA) is associated with a weakening of protective tumor immunity. Neoplasms of the skin in particular are known to exhibit increased incidence rates in association with therapeutic immunosuppression in transplantation medicine; however, the immunosuppression required for the prevention of allogenic graft rejection is much more intensive and thus not directly transferable to the potential risks for an onset or relapse of melanoma or non-melanoma skin cancers (NMSC), e. g. spinocellular and basal cell carcinomas in association with the antirheumatic treatment of RA. This review covers the association of RA and its pharmacotherapy with conventional synthetic (cs) and biologic disease-modifying antirheumatic drugs (DMARD) on the basis of a systematic literature search. The incidence rates of NMSC are twice as high in biologic-naive RA patients compared to the general population, whereas the respective incidence rates for melanoma do not differ. A biologic treatment with tumor necrosis factor (TNF) blockers compared with administration of csDMARD only has a minor, if any effect on the increase of NMSC risk but is associated with a trend towards an elevated incidence rate of new onset melanoma although significance level was not reached in all of the reviewed studies. The data on non-TNF blocking biologics is sparse. Accordingly, it is inappropriate to draw any strong conclusions on potentially associated skin cancer risks from the present lack of safety signals. The consideration of individual risk factors, recommendations on sufficient UV protection and regular skin monitoring may serve to improve the safety of DMARD therapy in RA.
authors.affiliation: Abteilung Rheumatologie & Fraunhofer IME, Projektgruppe Translationale Medizin und Pharmakologie Universitätsklinikum Frankfurt, Medizinische Klinik II, Goethe Universität Frankfurt am Main, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland. harald.burkhardt@kgu.de.
authors.forename: H
authors.initials: H
authors.lastname: Burkhardt
authors.affiliation: Dermatologikum Hamburg, Hamburg, Deutschland.
authors.forename: P
authors.initials: P
authors.lastname: Weisenseel
authors.affiliation: Institut für Versorgungsforschung in der Dermatologie, Universitätsklinikum Eppendorf, Hamburg, Deutschland.
authors.forename: M A
authors.initials: MA
authors.lastname: Radtke
authors.affiliation: Rheumatologisches Praxiszentrum St. Bonifatius, St. Bonifatius Str. 5, 81541, München, Deutschland.
authors.forename: K
authors.initials: K
authors.lastname: Krüger
mesh_terms: D000465:Algorithms; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000453:epidemiology*; D015897:Comorbidity; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000517:prevention & control*; D019317:Evidence-Based Medicine; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D015995:Prevalence; D012307:Risk Factors; D012878:Skin Neoplasms / Q000453:epidemiology* / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D007155:Immunologic Factors
keywords: Basal cell carcinoma; Biologics; Disease modifying antirheumatic drugs; Melanoma; Spinocellular carcinoma
references.citation: J Dtsch Dermatol Ges. 2013 Aug;11 Suppl 6:1-116, 1-126
references.pmid: 24028775
references.citation: Arthritis Rheumatol. 2014 Jun;66(6):1472-81
references.pmid: 24591475
references.citation: Rheumatology (Oxford). 2013 Jan;52(1):91-8
references.pmid: 23238979
references.citation: J Invest Dermatol. 2013 Aug;133(8):1950-5
references.pmid: 23344461
references.citation: J Rheumatol. 2005 Nov;32(11):2130-5
references.pmid: 16265690
references.citation: Ann Rheum Dis. 2012 Jun;71(6):869-74
references.pmid: 22241900
references.citation: Arch Dermatol Res. 2015 Dec;307(10):875-83
references.pmid: 26358263
references.citation: Int J Cancer. 2016 Jan 15;138(2):281-92
references.pmid: 25612559
references.citation: Ann Rheum Dis. 2013 Jan;72(1):79-82
references.pmid: 22945500
references.citation: Ann Rheum Dis. 2005 Oct;64(10):1421-6
references.pmid: 15829572
references.citation: J Eur Acad Dermatol Venereol. 2015 Apr;29(4):752-60
references.pmid: 25229823
references.citation: J Dtsch Dermatol Ges. 2013 Jun;11 Suppl 3:10-5, 11-6
references.pmid: 23734889
references.citation: Ann Rheum Dis. 2013 Apr;72(4):517-24
references.pmid: 22562972
references.citation: Arthritis Care Res (Hoboken). 2012 May;64(5):625-39
references.pmid: 22473917
references.citation: Br J Dermatol. 2015;172(5):1371-83
references.pmid: 25307931
references.citation: J Rheumatol. 2010 Nov;37(11):2205-15
references.pmid: 20810498
references.citation: Ann Rheum Dis. 2009 Jul;68(7):1136-45
references.pmid: 18753157
references.citation: Arthritis Care Res (Hoboken). 2010 Jun;62(6):755-63
references.pmid: 20535785
references.citation: BMJ. 2013 Apr 08;346:f1939
references.pmid: 23568792
references.citation: Arthritis Rheum. 2007 Sep;56(9):2886-95
references.pmid: 17729297
references.citation: Ann Rheum Dis. 2011 Nov;70(11):1895-904
references.pmid: 21885875